| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 17.083 | 19.313 | 15.326 | 12.841 | 12.015 | 17.587 | 37.056 | 32.347 | 33.306 | 32.195 |
| Total Income - EUR | 17.085 | 19.314 | 15.327 | 12.843 | 12.026 | 18.163 | 37.090 | 32.360 | 33.323 | 32.218 |
| Total Expenses - EUR | 20.514 | 23.206 | 12.036 | 10.957 | 12.983 | 12.771 | 12.573 | 16.942 | 18.464 | 16.916 |
| Gross Profit/Loss - EUR | -3.429 | -3.892 | 3.292 | 1.886 | -957 | 5.392 | 24.518 | 15.418 | 14.859 | 15.302 |
| Net Profit/Loss - EUR | -3.942 | -4.116 | 3.138 | 1.757 | -1.077 | 5.228 | 24.147 | 15.143 | 14.526 | 14.980 |
| Employees | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Cadavas Pharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 7.120 | 2.827 | 2.722 | 2.617 | 2.512 | 2.411 | 2.306 | 2.261 | 2.202 | 2.138 |
| Current Assets | 7.746 | 6.779 | 4.708 | 4.099 | 3.182 | 8.259 | 32.514 | 47.605 | 23.294 | 30.824 |
| Inventories | 0 | 0 | 562 | 551 | 541 | 530 | 519 | 520 | 963 | 958 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 2.705 | 0 | 653 | 260 |
| Cash | 7.746 | 6.779 | 4.146 | 3.548 | 2.641 | 7.728 | 29.290 | 47.085 | 21.678 | 29.606 |
| Shareholders Funds | 6.326 | 1.377 | 4.492 | 6.167 | 4.970 | 10.104 | 34.027 | 49.275 | 24.432 | 24.816 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 8.540 | 8.228 | 2.938 | 549 | 723 | 566 | 793 | 590 | 1.064 | 8.146 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7500 - 7500" | |||||||||
| CAEN Financial Year |
7500
|
|||||||||
Comments - Cadavas Pharm S.r.l.